LY 3114062

Drug Profile

LY 3114062

Alternative Names: LY-3114062

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Bispecific antibodies
  • Mechanism of Action Interleukin 17 modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Arthritis

Most Recent Events

  • 17 Jul 2018 LY 3114062 is still in phase I trials for Arthritis in Bulgaria, Georgia, Romania and Moldova (Eli Lilly pipeline, July 2018)
  • 01 Jun 2014 Phase-I clinical trials in Arthritis in Bulgaria and Moldova (IV)
  • 01 Jun 2014 Phase-I clinical trials in Arthritis in Bulgaria and Moldova (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top